Back to Journals » Drug Design, Development and Therapy » Volume 11

Development of highly potent melanogenesis inhibitor by in vitro, in vivo and computational studies

Authors Abbas Q, Ashraf Z, Hassan M, Nadeem H, Latif M, Afzal S, Seo S

Received 20 March 2017

Accepted for publication 8 May 2017

Published 5 July 2017 Volume 2017:11 Pages 2029—2046

DOI https://doi.org/10.2147/DDDT.S137550

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Sukesh Voruganti

Qamar Abbas,1 Zaman Ashraf,2 Mubashir Hassan,1 Humaira Nadeem,3 Muhammad Latif,4 Samina Afzal,5 Sung-Yum Seo1

1Department of Biology, College of Natural Sciences, Kongju National University, Gongju, Republic of Korea; 2Department of Chemistry, Allama Iqbal Open University, Islamabad, 3Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan; 4Center for Genetics and Inherited Diseases, Taibah University, Almadinah Almunawwarah, Kingdom of Saudi Arabia; 5Faculty of Pharmacy, Bahauddin Zakria University, Multan, Pakistan

Abstract: The present work describes the synthesis of few hydroxylated amide derivatives as melanogenesis inhibitors. In vitro, in vivo and computational studies proved that compound 6d is a highly potent melanogenesis inhibitor compared to standard kojic acid. The title amides 4a–e and 6a–e were synthesized following simple reaction routes with excellent yields. Most of the synthesized compounds exhibited good mushroom tyrosinase inhibitory activity, but compound 6d showed excellent activity (IC50 0.15 µM) compared to standard kojic acid (IC50 16.69 µM). Lineweaver–Burk plots were used for the determination of kinetic mechanism, and it was found that compounds 4c and 6d showed non-competitive inhibition while 6a and 6b showed mixed-type inhibition. The kinetic mechanism further revealed that compound 6d formed irreversible complex with the target enzyme tyrosinase. The Ki values determined for compounds 4c, 6a, 6b and 6d are 0.188, 0.84, 2.20 and 0.217 µM respectively. Results of human tyrosinase inhibitory activity in A375 human melanoma cells showed that compound 6d exhibited 91.9% inhibitory activity at a concentration of 50 µg/mL. In vivo cytotoxicity evaluation of compound 6d in zebrafish embryos showed that it is non-toxic to zebrafish. Melanin depigmentation assay performed in zebrafish indicated that compound 6d possessed greater potential in decreasing melanin contents compared to kojic acid at the same concentration. Computational studies also supported the wet lab findings as compound 6d showed a highest binding affinity with the target protein (PDBID: 2Y9X) with a binding energy value of -7.90 kcal/mol. Molecular dynamic simulation studies also proved that amide 6d formed the most stable complex with tyrosinase. Based upon our in vitro, in vivo and computational studies, we propose that compound 6d is a promising candidate for the development of safe cosmetic agent.

Keywords: melanogenesis, computational studies, tyrosinase inhibition, zebrafish, melanin quantification

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]